Meta-Analysis - Len maintenance post Auto-HCT

Background

Patient-level meta-analysis of 1,208 patients from three randomized controlled trials evaluating the impact of lenalidomide maintenance after autologous HCT on progression-free and overall survival in newly diagnosed multiple myeloma.

Interventions and follow up

Design: Pooled patient-level meta-analysis of CALGB 100104, GIMEMA RV-MM-PI-209, and IFM 2005-02
Arm A: Lenalidomide maintenance after autologous HCT
Arm B: Placebo or observation
Primary endpoint: Overall survival
Median follow-up: 79.5 months

Results

Median PFS: 52.8 months (lenalidomide) vs 23.5 months (placebo/observation)
Median OS: not reached vs 86 months; HR 0.75, 95% CI 0.63-0.90, P=.001

Adverse events

Second primary malignancy: Cumulative incidence before progression 5.5% (lenalidomide) vs 0.8% (placebo)
Hematologic: Neutropenia 2.3% vs 0.2%

Conclusions

Lenalidomide maintenance after autologous HCT conferred a significant overall survival benefit and confirmed the PFS benefit versus placebo/observation. Despite an increased risk of second primary malignancy, time to death from myeloma was significantly longer with lenalidomide, with no difference in death from second primary malignancy or adverse events between groups.

Key Limitations

Heterogeneity across the three source trials in maintenance dosing and duration and in control arms (placebo vs observation). Increased second primary malignancy risk requires individualized risk-benefit discussion. Predates routine triplet/quadruplet induction and MRD-guided strategies.

Clinical Context

This meta-analysis provided pivotal OS evidence supporting lenalidomide maintenance after autologous HCT and underpinned FDA/EMA approval of lenalidomide in this maintenance setting. Post-transplant lenalidomide maintenance is a standard of care per ASCO and ESMO guidance.

References